AR062409A1 - Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto - Google Patents

Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto

Info

Publication number
AR062409A1
AR062409A1 ARP070103654A ARP070103654A AR062409A1 AR 062409 A1 AR062409 A1 AR 062409A1 AR P070103654 A ARP070103654 A AR P070103654A AR P070103654 A ARP070103654 A AR P070103654A AR 062409 A1 AR062409 A1 AR 062409A1
Authority
AR
Argentina
Prior art keywords
independently
cycloalkyl
optionally
alkyl
haloalkyl
Prior art date
Application number
ARP070103654A
Other languages
English (en)
Spanish (es)
Inventor
Matthew Robert Johnson
Michael Sotirios Malamas
Keith Douglas Barnes
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR062409A1 publication Critical patent/AR062409A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP070103654A 2006-08-17 2007-08-16 Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto AR062409A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83835706P 2006-08-17 2006-08-17

Publications (1)

Publication Number Publication Date
AR062409A1 true AR062409A1 (es) 2008-11-05

Family

ID=38988046

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103654A AR062409A1 (es) 2006-08-17 2007-08-16 Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto

Country Status (9)

Country Link
EP (1) EP2054414A2 (fr)
JP (1) JP2010500999A (fr)
AR (1) AR062409A1 (fr)
CA (1) CA2660441A1 (fr)
CL (1) CL2007002288A1 (fr)
MX (1) MX2009001699A (fr)
PE (1) PE20080744A1 (fr)
TW (1) TW200817406A (fr)
WO (1) WO2008022024A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
AU2006259572A1 (en) 2005-06-14 2006-12-28 Schering Corporation Aspartyl protease inhibitors
EP2345411B1 (fr) 2005-06-14 2013-10-02 Merck Sharp & Dohme Corp. Inhibiteurs hétérocycliques d'aspartyl protéase, leurs préparations et utilisations
CA2628074C (fr) 2005-10-25 2014-01-14 Shionogi & Co., Ltd. Derive aminodihydrothiazine
US8168641B2 (en) 2006-06-12 2012-05-01 Schering Corporation Aspartyl protease inhibitors
CA2683887A1 (fr) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Derives d'aminodihydrothiazine substitues par un groupe cyclique ayant une activite inhibitoire contre la production de proteine beta amyloide
EP2151435A4 (fr) 2007-04-24 2011-09-14 Shionogi & Co Composition pharmaceutique pour le traitement de la maladie d'alzheimer
BRPI0911356A2 (pt) 2008-04-22 2019-09-24 Schering Corp compositos de 2-imino-3-metil pirrol pirimidina substituída por fenila como inibidores de bace-1, composições, e seu uso
JP5490692B2 (ja) 2008-06-13 2014-05-14 塩野義製薬株式会社 βセクレターゼ阻害作用を有する含硫黄複素環誘導体
EP2360155A4 (fr) 2008-10-22 2012-06-20 Shionogi & Co 2-aminopyridin-4-one et dérivé de 2-aminopyridine dont l'activité inhibe la bace1
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2511268B2 (fr) 2009-12-11 2021-02-17 Shionogi & Co., Ltd. Dérivé d'oxazine
EP2634186A4 (fr) 2010-10-29 2014-03-26 Shionogi & Co Dérivé de naphtyridine
US9018219B2 (en) 2010-10-29 2015-04-28 Shionogi & Co., Ltd. Fused aminodihydropyrimidine derivative
EP2694489B1 (fr) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. Composés de dioxyde de thiadiazine condensés avec des dérivés oxacycliques en c5-c6 comme inhibiteurs de bace, compositions, et utilisation use
WO2012138590A1 (fr) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. Composés de dioxyde de thiadiazine fusionnée à la pyrrolidine en tant qu'inhibiteurs de bace, compositions et leur utilisation
EP2703399A4 (fr) 2011-04-26 2014-10-15 Shionogi & Co Dérivé d'oxazine et inhibiteur de bace 1 le contenant
RU2014111055A (ru) 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
WO2014065434A1 (fr) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200602048A (en) * 2004-06-16 2006-01-16 Wyeth Corp Diphenylimidazopyrimidine and -imidazole amines as inhibitors of β -secretase
DE602005017033D1 (de) * 2004-06-16 2009-11-19 Wyeth Corp Amino-5,5-diphenylimidazolon-derivate zur beta-sekretase-hemmung
BRPI0606690A2 (pt) * 2005-01-14 2009-07-14 Wyeth Corp composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica
WO2007005404A1 (fr) * 2005-06-30 2007-01-11 Wyeth DÉRIVÉS D'IMIDAZOLONE PORTANT UN GROUPEMENT HÉTÉROARYLE À 6 CHAÎNONS EN POSITION 5 ET UN GROUPEMENT AMINO, ET LEUR EMPLOI DANS LA RÉGULATION DE LA β-SECRÉTASE
TW200738683A (en) * 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation

Also Published As

Publication number Publication date
CA2660441A1 (fr) 2008-02-21
PE20080744A1 (es) 2008-05-24
MX2009001699A (es) 2009-02-25
EP2054414A2 (fr) 2009-05-06
TW200817406A (en) 2008-04-16
WO2008022024A2 (fr) 2008-02-21
WO2008022024A3 (fr) 2008-05-22
CL2007002288A1 (es) 2008-02-08
JP2010500999A (ja) 2010-01-14

Similar Documents

Publication Publication Date Title
AR062409A1 (es) Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto
AR049399A1 (es) Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos
AR049551A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la beta-secretasa
PE20201165A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
NO20062704L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
PE20090556A1 (es) DERIVADOS DE 6-CICLOAMINO-3-(PIRIDIN-4-IL) IMIDAZO [1,2-b]-PIRIDAZINA COMO INHIBIDORES DE CASEINA QUINASAS Y SU PREPARACION
UY32483A (es) Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio
CY1116628T1 (el) Ενωσεις σπειρο-οξινδολιου και χρηση αυτων ως θεραπευτικοι παραγοντες
AR053092A1 (es) Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis
AR056536A1 (es) Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace)
PE20141110A1 (es) Derivados heterociclicos novedosos para el tratamiento de trastornos neurologicos
AR077505A1 (es) Compuestos de piridina y sus usos
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
UY28578A1 (es) Derivados de amida
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
RU2008142600A (ru) Органическое соединение
ATE464309T1 (de) Indolizinderivate und deren verwendung als crth2- antagonisten
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
AR078201A1 (es) Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos
EA200801001A1 (ru) Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
AR070810A1 (es) Derivados de 1- bencil-3-hidroximetilindazol y su utilizacion en el tratamiento de enfermedades basadas en la expresion de mcp-1 cx3cr1 y p40
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции

Legal Events

Date Code Title Description
FB Suspension of granting procedure